Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces the signing of a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE